CN113974001A - Application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate - Google Patents
Application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate Download PDFInfo
- Publication number
- CN113974001A CN113974001A CN202111342777.2A CN202111342777A CN113974001A CN 113974001 A CN113974001 A CN 113974001A CN 202111342777 A CN202111342777 A CN 202111342777A CN 113974001 A CN113974001 A CN 113974001A
- Authority
- CN
- China
- Prior art keywords
- cow
- perinatal
- parts
- mono
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013365 dairy product Nutrition 0.000 title claims abstract description 76
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 title claims abstract description 73
- 230000009984 peri-natal effect Effects 0.000 title claims abstract description 73
- 241000283690 Bos taurus Species 0.000 claims description 194
- 235000013336 milk Nutrition 0.000 claims description 26
- 239000008267 milk Substances 0.000 claims description 26
- 210000004080 milk Anatomy 0.000 claims description 26
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 24
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 22
- 244000068988 Glycine max Species 0.000 claims description 14
- 235000010469 Glycine max Nutrition 0.000 claims description 14
- 239000010902 straw Substances 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 229960000890 hydrocortisone Drugs 0.000 claims description 12
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 11
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 208000021129 Postpartum disease Diseases 0.000 claims description 9
- 235000020247 cow milk Nutrition 0.000 claims description 9
- 102000014171 Milk Proteins Human genes 0.000 claims description 8
- 108010011756 Milk Proteins Proteins 0.000 claims description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 8
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 8
- 235000021243 milk fat Nutrition 0.000 claims description 8
- 235000021239 milk protein Nutrition 0.000 claims description 8
- 210000001082 somatic cell Anatomy 0.000 claims description 8
- 240000005979 Hordeum vulgare Species 0.000 claims description 7
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 7
- 240000003183 Manihot esculenta Species 0.000 claims description 7
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 7
- 244000138286 Sorghum saccharatum Species 0.000 claims description 7
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 7
- 235000019764 Soybean Meal Nutrition 0.000 claims description 7
- 241000209140 Triticum Species 0.000 claims description 7
- 235000021307 Triticum Nutrition 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 7
- 235000005822 corn Nutrition 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 235000012054 meals Nutrition 0.000 claims description 7
- 239000004460 silage Substances 0.000 claims description 7
- 239000004455 soybean meal Substances 0.000 claims description 7
- 239000003674 animal food additive Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000007976 Ketosis Diseases 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 206010046793 Uterine inflammation Diseases 0.000 claims description 5
- 210000003165 abomasum Anatomy 0.000 claims description 5
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 230000004140 ketosis Effects 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 2
- 210000002219 extraembryonic membrane Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002180 anti-stress Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 238000009395 breeding Methods 0.000 abstract description 2
- 230000001488 breeding effect Effects 0.000 abstract description 2
- 244000144972 livestock Species 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000008642 heat stress Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
- A23K50/15—Feeding-stuffs specially adapted for particular animals for ruminants containing substances which are metabolically converted to proteins, e.g. ammonium salts or urea
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
- A23K10/37—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Abstract
The invention relates to application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate, and belongs to the field of livestock breeding and the field of biology. The dairy cow feed comprises monoammonium glycyrrhizinate, and when the dairy cow feed is fed to a perinatal dairy cow, the anti-stress capability of the dairy cow can be improved, and the health condition of the dairy cow can be improved.
Description
Technical Field
The invention relates to application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate, and belongs to the field of livestock breeding and the field of biology.
Background
The perinatal period of cows includes the peripartum early period (3 weeks before the birth) and the perinatal late period (3 weeks after the birth), which are important turning periods in the lactation period. The dairy cows are confronted with the rapid growth of fetuses in the later stage of pregnancy and the initiation of postpartum lactation, and the requirements on nutrition and energy are increased; the hormone level can also change along with the rapid physiological transformation, adapt to and regulate the physiological transformation process of the organism, and the perinatal period faces huge stress response. Reducing the stress of the dairy cows in the perinatal period can effectively reduce the occurrence of diseases of the dairy cows in the perinatal period and improve the production performance of the dairy cows.
Disclosure of Invention
The invention aims to provide the perinatal dairy cow feed for improving the anti-stress capability of dairy cows and improving the health condition of the dairy cows.
The second purpose of the invention is to provide an application of monoammonium glycyrrhizinate in increasing milk yield of cows or increasing the milk fat rate of cows or increasing the milk protein rate of cows or reducing the somatic cell number of cows or reducing the urea nitrogen content of cows.
The third purpose of the invention is to provide an application of mono-ammonium glycyrrhizinate in preparing perinatal drugs for reducing the incidence of postpartum diseases of dairy cows.
The fourth purpose of the invention is to provide an application of monoammonium glycyrrhizinate in reducing cortisol concentration in a cow, or increasing total antioxidant capacity concentration in a cow, or increasing glutathione peroxidase concentration in a cow, or reducing nitric oxide concentration or neutral in a cow.
The fifth purpose of the invention is to provide the application of the mono-ammonium glycyrrhizinate as the feed additive for the dairy cows in the perinatal period.
In order to realize the purpose, the technical scheme of the perinatal cow feed provided by the invention is as follows:
a perinatal milk cow feed comprises monoammonium glycyrrhizinate.
The perinatal dairy cow feed contains the monoammonium glycyrrhizinate, and can improve the anti-stress capability and the health condition of dairy cows when the perinatal dairy cows are fed with the feed. The monoammonium glycyrrhizinate of the invention is monoammonium glycyrrhizinate of a licorice extract.
Preferably, the mass fraction of the mono-ammonium glycyrrhizinate in the perinatal cow feed is 0.005-0.05%. Further, the mass fraction of the ammonium glycyrrhizinate in the perinatal dairy cow feed is 0.008-0.016%.
Preferably, the perinatal cow feed consists of the following components in parts by mass: 4.5-5.5 parts of wheat straw, 18-22 parts of sweet sorghum straw, 30-35 parts of corn silage, 4.5-6 parts of pearl barley, 0.4-1 part of cassava residue, 1.5-2.5 parts of soybean hull, 0.5-1 part of full-fat soybean, 5.5-6.5 parts of soybean meal, 0.4-1 part of palm kernel meal, 0.1-0.2 part of glutamic acid residue, 0.4-1 part of premix, 0.2-0.5 part of yeast culture and 0.005-0.05 part of monoammonium glycyrrhizinate. Further, the perinatal period dairy cow feed comprises the following components in parts by mass: 4.650 parts of wheat straw, 20.926 parts of sweet sorghum straw, 32.540-32.546 parts of corn silage, 5.094 parts of pearl barley, 0.488 part of cassava residue, 2.279 parts of soybean hull, 0.591 part of full-fat soybean, 6.466 parts of soybean meal, 0.488 part of palm kernel meal, 0.163 part of glutamic acid residue, 0.488 part of premix, 0.233 part of yeast culture and 0.006-0.012 part of monoammonium glycyrrhizinate.
The premix is used for providing minerals, trace elements and vitamins, and can supplement vitamins and minerals required by the metabolism of the dairy cows. The yeast culture is used for providing various active substances, such as polysaccharide, probiotics and the like, and the yeast culture is helpful for improving the immunity and the intestinal health of the dairy cows.
Preferably, the perinatal cow feed is uniformly mixed with a proper amount of water when in use, and the mass ratio of the perinatal cow feed to the water is (66.005-82.25): (17.75-33.995). Further, the mass ratio of the perinatal cow feed to the water is 74.418: 25.582.
The technical scheme of the application of the monoammonium glycyrrhizinate in improving the milk yield of the cow, or improving the milk fat rate of the cow, or improving the milk protein rate of the cow, or reducing the somatic cell number of the cow, or reducing the urea nitrogen content of the cow is as follows:
the application of the mono-ammonium glycyrrhizinate in improving the milk yield of the dairy cow, or improving the milk fat rate of the milk, or improving the milk protein rate of the milk, or reducing the somatic cell number of the milk, or reducing the urea nitrogen content of the milk is used for feeding or injecting the mono-ammonium glycyrrhizinate to the dairy cow in the perinatal period.
Compared with the cow feed without the mono-ammonium glycyrrhizinate, when the cow feed with the mono-ammonium glycyrrhizinate is used for feeding the cow in the perinatal period, the milk yield of the cow can be improved, the milk fat rate of the cow milk can be improved, the milk protein rate of the cow milk can be improved, the somatic cell number of the cow milk can be reduced, and the urea nitrogen content of the cow milk can be reduced.
The technical scheme of the application of the mono-ammonium glycyrrhizinate in preparing the perinatal medicament for reducing the incidence of postpartum diseases of the dairy cows is as follows:
the application of the mono-ammonium glycyrrhizinate in preparing the perinatal medicament for reducing the incidence rate of postpartum diseases of the dairy cows is to feed or inject the mono-ammonium glycyrrhizinate into the dairy cows in the perinatal period.
Preferably, the disease is one or any combination of ketosis, retained fetal membranes, postpartum paralysis, abomasum displacement and metritis.
Compared with the cow feed without the mono-ammonium glycyrrhizinate, when the cow feed with the mono-ammonium glycyrrhizinate is used for feeding the perinatal cows, the probability of the cows to suffer from ketosis, retained afterbirth, postpartum paralysis, abomasum displacement and metritis after delivery is reduced.
The technical scheme of the application of the monoammonium glycyrrhizinate in reducing the concentration of cortisol in a milk cow body or improving the concentration of total antioxidant capacity in the milk cow body or improving the concentration of glutathione peroxidase in the milk cow body or reducing the concentration of nitric oxide in the milk cow body is as follows:
the application of the mono-ammonium glycyrrhizinate in reducing the concentration of cortisol in a cow body or improving the concentration of total antioxidant capacity in the cow body or improving the concentration of glutathione peroxidase in the cow body or reducing the concentration of nitric oxide in the cow body is used for feeding or injecting the mono-ammonium glycyrrhizinate to the cow in the perinatal period.
Preferably, the application of the monoammonium glycyrrhizinate in reducing the concentration of cortisol in the serum of the dairy cow, or increasing the concentration of the total antioxidant capacity in the serum of the dairy cow, or increasing the concentration of glutathione peroxidase in the serum of the dairy cow, or reducing the concentration of nitric oxide in the serum of the dairy cow, the monoammonium glycyrrhizinate is fed to the dairy cow in the perinatal period.
Compared with the dairy cow feed without the mono-ammonium glycyrrhizinate, when the dairy cow feed with the mono-ammonium glycyrrhizinate is used for feeding the dairy cows in the perinatal period, the concentration of cortisol in the serum of the dairy cows is reduced, and the heat shock reaction generated when the dairy cows are subjected to heat stress can be reduced; compared with the dairy cow feed without the mono-ammonium glycyrrhizinate, when the dairy cow feed with the mono-ammonium glycyrrhizinate is used for feeding the perinatal dairy cows, the total antioxidant capacity T-AOC in the serum of the dairy cows is improved, and the influence of heat stress on the dairy cows can be reduced; compared with the dairy cow feed without the mono-ammonium glycyrrhizinate, when the dairy cow feed with the mono-ammonium glycyrrhizinate is used for feeding the dairy cow in the perinatal period, the concentration of glutathione peroxidase in the serum of the dairy cow is increased; compared with the cow feed without the mono-ammonium glycyrrhizinate, when the cow feed with the mono-ammonium glycyrrhizinate is used for feeding the perinatal cows, the concentration of nitric oxide in the serum of the cows is reduced.
The technical scheme of the application of the mono-ammonium glycyrrhizinate serving as the perinatal cow feed additive is as follows:
the application of the mono-ammonium glycyrrhizinate as a perinatal cow feed additive.
When the perinatal dairy cattle are fed with the perinatal dairy cattle feed containing the monoammonium glycyrrhizinate serving as the perinatal dairy cattle feed additive, the anti-stress capability of the dairy cattle can be improved, and the health condition of the dairy cattle can be improved.
Drawings
Fig. 1 is a graph of cortisol concentration in the serum of different groups of cows in example 5 as a function of experimental days, where "□" indicates a significant difference between group a and group B (P <0.05), ". means a significant difference between group a and group C (P < 0.05);
fig. 2 is a graph of the concentration of total antioxidant capacity in serum of different groups of cows in example 5 as a function of experimental days, wherein ″ "means that group a is significantly different from group C (P < 0.05);
FIG. 3 is a graph showing the change of the concentration of superoxide dismutase in the serum of different groups of cows in example 5 with the day of the experiment;
FIG. 4 is a graph showing the variation of catalase concentration in serum of different groups of cows in example 5 with the number of days of experiment;
FIG. 5 is a graph showing the change in serum concentration of malondialdehyde in the sera of different groups of cows in example 5 over the days of the experiment;
FIG. 6 is a graph showing the change of glutathione peroxidase concentration in serum of different groups of cows in example 5 with the number of days of experiment;
fig. 7 is a graph showing the variation of nitric oxide concentration in serum of cows of different groups in example 5 with days of experiment, wherein "□" indicates that group a is significantly different from group B (P < 0.05).
Detailed Description
The technical solution of the present invention will be further explained with reference to the specific embodiments. It should be noted that the purpose of this embodiment is to further illustrate the present invention, and not to limit the protection scope of the present invention.
The raw materials used in the examples: the glutamic acid residue is produced by the flourishing chemical company Limited of Jinan, CAS: 1548-5-3; the premix is produced by Yinjupaxin technology limited company, and the product model is 1 percent of the compound premix for the dairy cows; yeast cultures were produced by the company Bioyang Ogaku Biotech GmbH under the product model of Biakalin C +.
The experimental materials in the examples are as follows:
experimental animals: selecting Holstein cows with 2-5 fetuses, body condition scores (3.0 +/-0.5) and similar physiological states as experimental animals; feeding conditions are as follows: all experimental animals can eat and drink water freely.
Experimental groups in example 3, example 4 and example 5 are as follows:
the experimental animals in the examples were randomized into 3 groups (15 animals each), each: group A, group B and group C. According to the weight of the cattle, the amount of the cow feed fed to each kg of cattle is 0.0331kg, and the feeding period is 21 days before birth to 21 days after birth.
Group A: feeding the cow feed of the comparative example every day for 42 days, and then feeding the original daily ration;
group B: the cow feed of example 1 was fed daily for 42 days, then the same ration as in group a was fed;
group C: the cows of example 2 were fed daily for 42 days and then fed the same ration as group a;
example 1
The perinatal period dairy cow feed comprises the following components in parts by mass: 4.650 parts of wheat straw, 20.926 parts of sweet sorghum straw, 32.546 parts of corn silage, 5.094 parts of pearl barley, 0.488 part of cassava residue, 2.279 parts of soybean hull, 0.591 part of full-fat soybean, 6.466 parts of soybean meal, 0.488 part of palm kernel meal, 0.163 part of glutamic acid residue, 0.488 part of premix, 0.233 part of yeast culture and 0.006 part of monoammonium glycyrrhizinate; the perinatal cow feed of the embodiment is mixed with a proper amount of water when in use, and the mass ratio of the perinatal cow feed to the water is 74.418: 25.582.
Example 2
The perinatal period dairy cow feed comprises the following components in parts by mass: 4.650 parts of wheat straw, 20.926 parts of sweet sorghum straw, 32.540 parts of corn silage, 5.094 parts of pearl barley, 0.488 part of cassava residue, 2.279 parts of soybean hull, 0.591 part of full-fat soybean, 6.466 parts of soybean meal, 0.488 part of palm kernel meal, 0.163 part of glutamic acid residue, 0.488 part of premix, 0.233 part of yeast culture and 0.012 part of monoammonium glycyrrhizinate; the perinatal cow feed of the embodiment is mixed with a proper amount of water when in use, and the mass ratio of the perinatal cow feed to the water is 74.418: 25.582.
Comparative example
The perinatal period dairy cow feed of the comparative example comprises the following components in parts by mass: 4.650 parts of wheat straw, 20.926 parts of sweet sorghum straw, 32.552 parts of corn silage, 5.094 parts of pearl barley, 0.488 part of cassava residue, 2.279 parts of soybean hull, 0.591 parts of full-fat soybean, 6.466 parts of soybean meal, 0.488 part of palm kernel meal, 0.163 part of glutamic acid residue, 0.488 part of premix and 0.233 part of yeast culture; the perinatal cow feed of the comparative example is mixed with a proper amount of water when in use, and the mass ratio of the perinatal cow feed to the water is 74.418: 25.582.
Example 3: relates to the relationship between monoammonium glycyrrhizinate and the milk yield and milk quality of dairy cows.
1. Experimental procedure
The daily milk yield of the cows is recorded during the experiment, milk samples of the 1 st day, the 14 th day and the 28 th day of the experiment are collected, and the milk fat rate, the milk protein rate, the somatic cell number and the urea nitrogen content of the cow milk are analyzed.
2. Results of the experiment
The results obtained from the experiments are shown in table 1, and as can be seen from table 1, compared with the group a cows, the average milk yields of the cows in the group B and the group C are respectively improved by 0.62kg and 1.15kg, the milk fat rates are respectively improved by 0.76 and 0.39 percentage points, the milk protein rates are respectively improved by 0.05 and 0.19 percentage points, but the difference between the groups is not significant (P > 0.05); monoammonium glycyrrhizinate can significantly reduce the number of somatic cells in milk (P ═ 0.033). Compared with the group A cows, the urea nitrogen concentration of the cows in the group B and the cows in the group C is improved, but the difference is not significant (P > 0.05).
TABLE 1 relationship between monoammonium glycyrrhizinate and milk quality of cows
Note: the data in table 1 are all expressed as "Mean ± standard error (Mean ± SEM)"; the difference of the shoulder mark letters of each row of data indicates significant difference (P < 0.05).
Therefore, the monoammonium glycyrrhizinate has the functions of improving the milk yield of the cow, improving the milk fat rate of the cow, improving the milk protein rate of the cow, reducing the somatic cell number of the cow and reducing the urea nitrogen content of the cow.
Example 4: the relationship between monoammonium glycyrrhizinate and the incidence of postpartum diseases of dairy cows.
1. Experimental procedure
The morbidity of the test cattle within 60 days after delivery is recorded through DelPro pasture management software, including last morbidity type and morbidity interval time, statistical data are analyzed, and the influence of ammonium glycyrrhizinate on the morbidity of common postpartum diseases of the dairy cattle in the perinatal period is evaluated.
2. Results of the experiment
The secondary multiple diseases of the cows after delivery are easy to be acquired, the morbidity of common diseases of the cows after calving is counted and tested, the experimental results are shown in the table 2, and compared with the group A, the probability that the cows of the group B and the group C have 5 common diseases of ketosis, retained afterbirth, postpartum paralysis, abomasum displacement and metritis is not significantly different from that of the control group (P is more than 0.05). Statistics of the total number of cattle with disease revealed that group B and group C perinatal cows had lower incidence than the control group compared to group a, with group B being significantly lower than group a (P < 0.05).
TABLE 2 relationship between monoammonium glycyrrhizinate and postpartum disease incidence of dairy cows
Note: table 2 shows significant differences (P <0.05) between each row of data and the shoulder letters.
Therefore, the monoammonium glycyrrhizinate has the function of reducing the probability of the dairy cattle to have ketosis, retained afterbirth, postpartum paralysis, abomasum displacement and metritis after delivery, and can be used for preparing perinatal medicaments for reducing the incidence of postpartum diseases of the dairy cattle.
Example 5: the relationship between monoammonium glycyrrhizinate and cortisol concentration in a milk cow, total antioxidant capacity concentration in the milk cow, glutathione peroxidase concentration in the milk cow and nitric oxide concentration in the milk cow is disclosed.
1. Experimental procedure
Collecting tail vein blood of all test cows at 1, 7, 14, 21 and 28 days after delivery, centrifuging 10mL each to separate out serum at normal temperature for 10min at 300g, collecting supernatant, storing at-20 deg.C for examination, detecting Cortisol (Cortisol) concentration in serum by ELISA, detecting Total antioxidant capacity (T-AOC) concentration in serum of cows by ABTS, detecting Superoxide dismutase (SOD) activity in serum of cows by WST-1, detecting Catalase (CAT) concentration in serum of cows by ELISA, Malondialdehyde (Malondialdehyde, MDA) concentration in serum by TBA, and Glutathione peroxidase (GSH-PX) concentration in serum of cows by Griess, and detecting Nitric oxide (NO, NO) concentration in serum of cows by NIE.
2. Results of the experiment
The cortisol concentrations in the sera of cows in groups a, B and C are shown in fig. 1, and it can be seen from fig. 1 that the cortisol concentrations in the sera of cows in groups B and C are reduced compared to cows in group a, with significant differences (P <0.05) between groups B and C on both days 14 and 21 of the trial compared to group a. Therefore, the monoammonium glycyrrhizinate can reduce the stress response of the dairy cows in the perinatal period.
The total antioxidant capacity, superoxide dismutase, catalase and malondialdehyde in the serum of the group A, group B and group C cows are shown in figure 2, figure 3, figure 4 and figure 5, and it can be seen from figure 2 that the total antioxidant capacity in the serum of the group B and group C cows is higher than that of the group A cows, and the total antioxidant capacity in the serum of the group C cows is significantly improved (P <0.05) compared with that of the group A cows at the 7 th day of the test. As can be seen from fig. 3, fig. 4 and fig. 5, there was no significant effect on SOD activity, CAT and MDA concentrations in serum of group a, group B and group C cows (P > 0.05).
The concentration of glutathione peroxidase in the serum of group a, group B and group C cows is shown in fig. 6, and it can be seen from fig. 6 that the concentration of GSH-PX in the serum of group B cows is higher than that of group a at the overall level, and the difference is not significant (P > 0.05).
The concentration of nitric oxide in the serum of the cows in the group A, the group B and the group C is shown in figure 7, and as can be seen from figure 7, the concentration of NO in the serum of the cows in the group B is lower than that of the cows in the group A on the 14 th to 28 th days of the test, and the difference is significant (P <0.05) on the 14 th day.
Therefore, the ammonium glycyrrhizinate has the function of reducing the concentration of cortisol in the serum of the dairy cow, and can reduce the heat shock reaction generated when the dairy cow is subjected to heat stress; the monoammonium glycyrrhizinate has the function of improving the concentration of the total antioxidant capacity in the serum of the dairy cows; the monoammonium glycyrrhizinate has the function of improving the concentration of glutathione peroxidase in the serum of the dairy cows; the ammonium glycyrrhizinate has the function of reducing the concentration of nitric oxide in the serum of the dairy cow.
Example 6
In the embodiment, the mono-ammonium glycyrrhizinate is added into the perinatal cow feed as a perinatal cow feed additive, and the obtained perinatal cow feed is fed to the perinatal cows.
Claims (10)
1. A perinatal dairy cow feed, which is characterized by comprising monoammonium glycyrrhizinate.
2. The perinatal cow feed according to claim 1, wherein the mass fraction of the ammonium glycyrrhizinate in the perinatal cow feed is 0.005-0.05%.
3. The perinatal cow feed according to claim 2, wherein the mass fraction of the ammonium glycyrrhizinate in the perinatal cow feed is 0.008-0.016%.
4. The perinatal cow feed as claimed in claim 2 or 3, wherein the perinatal cow feed consists of the following components in parts by mass: 4.5-5.5 parts of wheat straw, 18-22 parts of sweet sorghum straw, 30-35 parts of corn silage, 4.5-6 parts of pearl barley, 0.4-1 part of cassava residue, 1.5-2.5 parts of soybean hull, 0.5-1 part of full-fat soybean, 5.5-6.5 parts of soybean meal, 0.4-1 part of palm kernel meal, 0.1-0.2 part of glutamic acid residue, 0.4-1 part of premix, 0.2-0.5 part of yeast culture and 0.005-0.05 part of monoammonium glycyrrhizinate.
5. The perinatal cow feed according to claim 4, wherein the perinatal cow feed consists of the following components in parts by mass: 4.650 parts of wheat straw, 20.926 parts of sweet sorghum straw, 32.540-32.546 parts of corn silage, 5.094 parts of pearl barley, 0.488 part of cassava residue, 2.279 parts of soybean hull, 0.591 part of full-fat soybean, 6.466 parts of soybean meal, 0.488 part of palm kernel meal, 0.163 part of glutamic acid residue, 0.488 part of premix, 0.233 part of yeast culture and 0.006-0.012 part of monoammonium glycyrrhizinate.
6. Use of mono-ammonium glycyrrhizinate for increasing milk production in dairy cows or increasing the milk fat fraction in cow's milk or increasing the milk protein fraction in cow's milk or reducing the somatic cell count in cow's milk or reducing the urea nitrogen content in cow's milk, characterized in that mono-ammonium glycyrrhizinate is fed to or injected into dairy cows in perinatal period.
7. The application of the mono-ammonium glycyrrhizinate in preparing the perinatal medicament for reducing the incidence rate of postpartum diseases of the dairy cows is characterized in that the mono-ammonium glycyrrhizinate is fed to the dairy cows in the perinatal period or injected.
8. The use of mono-ammonium glycyrrhizinate for the preparation of a perinatal drug for reducing the incidence of postpartum diseases in dairy cows according to claim 7, wherein the diseases are one or any combination of ketosis, retained fetal membranes, postpartum paralysis, displacement of the true stomach and metritis.
9. The application of the mono-ammonium glycyrrhizinate in reducing the concentration of cortisol in a cow body or improving the concentration of total antioxidant capacity in the cow body or improving the concentration of glutathione peroxidase in the cow body or reducing the concentration of nitric oxide in the cow body is characterized in that the mono-ammonium glycyrrhizinate is fed or injected to the cow in the perinatal period.
10. The application of the mono-ammonium glycyrrhizinate as a perinatal cow feed additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111342777.2A CN113974001A (en) | 2021-11-12 | 2021-11-12 | Application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111342777.2A CN113974001A (en) | 2021-11-12 | 2021-11-12 | Application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113974001A true CN113974001A (en) | 2022-01-28 |
Family
ID=79748327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111342777.2A Pending CN113974001A (en) | 2021-11-12 | 2021-11-12 | Application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113974001A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1479626A (en) * | 2000-12-12 | 2004-03-03 | ��Ԩ��ѧ��ҵ��ʽ���� | Compositions for preventing or ameliorating multiple risk factor syndromes |
| US20070116833A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition with Calcium and Compositions Sweetened Therewith |
| CN102987082A (en) * | 2011-09-15 | 2013-03-27 | 上海美农生物科技股份有限公司 | Composite feed sweetening agent having sucrose taste, and preparation method thereof |
| CN104323006A (en) * | 2014-10-30 | 2015-02-04 | 科尔沁牛业南阳有限公司 | Special feed for dairy cattle as well as preparation method and feeding method of special feed for dairy cattle |
| CN105358166A (en) * | 2013-05-17 | 2016-02-24 | 可尔必思株式会社 | Preventive or therapeutic agent for ruminant animal mastitis |
| CN111068074A (en) * | 2018-10-19 | 2020-04-28 | 阿瓦隆·海帕波有限公司 | Galactose oral composition and application thereof |
-
2021
- 2021-11-12 CN CN202111342777.2A patent/CN113974001A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1479626A (en) * | 2000-12-12 | 2004-03-03 | ��Ԩ��ѧ��ҵ��ʽ���� | Compositions for preventing or ameliorating multiple risk factor syndromes |
| US20070116833A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition with Calcium and Compositions Sweetened Therewith |
| CN102987082A (en) * | 2011-09-15 | 2013-03-27 | 上海美农生物科技股份有限公司 | Composite feed sweetening agent having sucrose taste, and preparation method thereof |
| CN105358166A (en) * | 2013-05-17 | 2016-02-24 | 可尔必思株式会社 | Preventive or therapeutic agent for ruminant animal mastitis |
| CN104323006A (en) * | 2014-10-30 | 2015-02-04 | 科尔沁牛业南阳有限公司 | Special feed for dairy cattle as well as preparation method and feeding method of special feed for dairy cattle |
| CN111068074A (en) * | 2018-10-19 | 2020-04-28 | 阿瓦隆·海帕波有限公司 | Galactose oral composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 蒋辰宇: ""甘草酸单铵盐对绵羊瘤胃甲烷产生的关键菌群、相关代谢产物及血液生化指标的影响"", 《中国优秀硕士学位论文全文数据库》, no. 8, pages 2 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101305774B (en) | Cow compound nutritional supplement at perinatal period | |
| CN101836699B (en) | Milk cow irrigation liquid for protecting milk cow from safely getting through latter perinatal period | |
| CN106806374B (en) | A kind of composition for preventing and treating perinatal period ruminant ketoacidosis and fatty liver | |
| CN102113628A (en) | Milch cow feed capable of improving milk quality and preparation method and application thereof | |
| CN105685464A (en) | A dairy cattle feed additive and a breeding method for dairy cattle in an early perinatal period | |
| CN111034674A (en) | Nutritional feed set for feeding Tibetan lambs weaned in advance under grazing condition and method for feeding Tibetan lambs weaned in advance | |
| EP1157616B1 (en) | Feed for livestock | |
| CN102578413A (en) | Feed for breeding sows | |
| CN106616065A (en) | Additive capable of enhancing non-specific immunity function of macrobrachium rosenbergii | |
| CN101731481B (en) | Milk cow premix compound and preparation method thereof | |
| CN113974001A (en) | Application of perinatal dairy cow feed and mono-ammonium glycyrrhizinate | |
| CN108684954A (en) | A kind of breastfeeding sow compound feed and preparation method thereof improving lactation amount | |
| Quanwei et al. | Effect of pelleted total mixed ration on production performance and serum biochemical index of Growin Hainan Black goats | |
| CN113367240A (en) | Biological fermentation feed for lactating sows and preparation method thereof | |
| CN111972553A (en) | Perinatal period dairy cow nutrition supplement and preparation method thereof | |
| CN107912625B (en) | Antibiotic-free functional concentrated feed for lactating sows | |
| CN101878864B (en) | Rumen health-care agent for milk cows and preparation method thereof | |
| CN113439804A (en) | Gynostemma pentaphylla composition for obese cows in late lactation period and preparation method and application thereof | |
| CN109043146A (en) | A kind of feed addictive for milk cattle beneficiated burden material complemental feed | |
| Medhi et al. | Effect of plane of nutrition on blood biochemical parameters and attainment of sexual maturity in growing yaks | |
| EP0341847B1 (en) | Ruminant animal feedstuffs | |
| Puri et al. | Effect of feeding protected protein supplemented with urea-treated straw on performance of buffalo calves | |
| Ovsiienko | METHOD OF PREVENTING HIGH-YIELDING COWS'KETOSIS | |
| CN105850872A (en) | Method for cultivating high-yield Huang-Huai ewes | |
| Martinez et al. | Effects of feeding a fibrolytic enzyme to Holstein dairy cows on milk production and reproduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |